#ALAmyloidosis?
Accurate differentiation between light-chain (AL) amyloidosis and #ATTRCM is critical for effective patient management, as misclassification can delay life-saving therapies for #ALAmyloidosis or result in unnecessary interventions for ATTR-CM.

Learn more: https://bit.ly/4q8BrAH
AL Amyloidosis vs ATTR-CM: Clinical Insights and Diagnostic Challenges
This article explores key differences and diagnostic challenges between light-chain amyloidosis and ATTR-CM.
bit.ly
January 6, 2026 at 8:54 PM
MPE is attending the @ash.hematology.org annual congress in Orlando, Florida. Over the next few days, we will follow the key updates in #myeloma and #ALamyloidosis and speak with leading experts to understand what they mean for patients.
#ASH25
December 5, 2025 at 1:29 PM
Margherita Romeo & co generate the first transgenic C. elegans strain as a model of immunoglobulin light chain amyloidosis to investigate the mechanisms underlying the cardiac-specific toxicity occurring in the disease.
doi.org/10.1242/dmm....

#ALAmyloidosis
September 8, 2025 at 1:26 PM
Light chain dimers in native conditions are not all the same, check what we found! #alAmyloidosis
July 14, 2024 at 7:47 AM
Study S2213 is for people with newly diagnosed #ALAmyloidosis. It compares a combination of immunotherapy and chemo drugs (called Dara-VCD) to stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. Ask about S2213. #raredisease #mmsm
November 26, 2025 at 2:25 PM
Have you tuned into ‘Navigating AL Amyloidosis’ yet? Don’t miss our expert podcast series, hosted by Dr Shaji Kumar, covering key topics from avoiding diagnostic delay to the patient’s perspective #MedSky #MedicalEducation #ALAmyloidosis

ow.ly/8Ecl50VJNIA
April 29, 2025 at 3:17 PM
Enrolling: SWOG S2213 in newly diagnosed #ALamyloidosis. Daratumumab + VCD induction, then randomization to autologous stem cell transplant or Dara-VCD consolidation. Patients on both arms get dara maintenance.
Co-PI: @surbhisidanamd.bsky.social Stanford Medicine
SWOG.org/clinical-trials/S2213
December 5, 2025 at 4:50 PM
Sharing our trial in progress, IMPACT AL, testing teclistamab combined with daratumumab in newly diagnosed #alamyloidosis at #ASH25 meetin. Excited to work with Drs Chakraborty, Lentzsch, and Sanchorawala, with funding from J&J and SU2C.
December 6, 2025 at 11:36 PM
Elranatamab treatment of patients with advanced immunoglobulin light-chain #amyloidosis resulted in a 100% overall response rate. Published in @bloodjournals.hematology.org.

https://bit.ly/4s4uSR7

#ALAmyloidosis
Elranatamab May Be Effective for Light Chain Amyloidosis
Researchers determined elranatamab may be an effective treatment for patients with advanced immunoglobulin light-chain amyloidosis and further study is warranted.
bit.ly
December 22, 2025 at 6:07 PM
What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates.
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
December 15, 2025 at 8:00 PM
My #ASH24 highlights from yesterday were the talks that emphasised the importance of increasing awareness of #MGUS, monoclonal gammopathies of clinical significance like #MGRS and #MGNS, and #ALAmyloidosis so patients can be diagnosed earlier.
December 9, 2024 at 6:30 PM
The new AL International Staging System (AL-ISS) is here, defining Stage IIIC as an ultra-poor risk. Simultaneous publication at #ASH25! This is a major step for diagnosis and patient care.

👉 Read the full abstract: brnw.ch/21wYb73
#ALamyloidosis #Hematology
December 8, 2025 at 3:43 PM
The @fda.gov has granted traditional approval to Darzalex Faspro® in combination with VCd for the treatment of adults with newly diagnosed #ALAmyloidosis. From @medicalprofref.bsky.social.

https://bit.ly/44hz4Tm
FDA Grants Traditional Approval to Darzalex Faspro for AL Amyloidosis
The FDA has granted traditional approval to Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adults with newly diagnosed light chain amyloidosis.
bit.ly
November 29, 2025 at 9:15 PM
July 29, 2025 at 2:07 PM
Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease
December 12, 2025 at 1:55 PM
S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.
January 6, 2026 at 8:15 PM
#ALamyloidosis is a rare condition characterized by the deposition of immunoglobulin light chains in organs. The ANDROMEDA study assessed the addition of DARA to the standard VCd regimen. Read the results: journals.lww.com/oncology-tim...
March 27, 2025 at 3:09 PM